PTN 241220 5.00P (PTN241220P5000) Stock Options, News & Quotes

0.00
0.000.00%

15min DelayClose Dec 20 09:30 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Yesterday 07:46

🟢 Watchlist FRIDAY December 20,2024. N F A !

NOTE!
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Aadi Biosciences (AADI.US)$ PR AH 12/...

Jaguar8

Dec 19 06:32

NEWS

$Palatin Technologies (PTN.US)$
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Thursday, 19th December at 7:30 am
• Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy
• Demonstrated efficacy at 6 months
◦ 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr)
◦ 71% of patients achieved improved or stab...

Trytosaveabit

Dec 19 06:30

News

$Palatin Technologies (PTN.US)$ Reuters· just
Palatin Announces Positive Phase Iib Breakout Study Results in Patients With Type 2 Diabetic Nephropathy! Palatin Technologies Inc - Bremelanotide Well Tolerated With No Serious Adverse Events

The Flow

Nov 14 12:58

I am feeling it!!!

Share Your Profit/Loss

Jaguar8

Oct 31 06:35

NEWS

$Palatin Technologies (PTN.US)$
Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
• Topline results expected in 1Q calendar year 2025
• Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight
• Data will inform and support the Company's obesity programs using novel, long-acting and highly selective MC4R peptide and small molecule compoun...